Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway...

Area of Science:

• Pulmonology
• Immunology
• Virology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, presents significant challenges due to severe lung complications like ARDS.
• The precise molecular mechanisms and cellular targets of SARS-CoV-2 remain incompletely understood.
• A hyperactive immune response is implicated in COVID-19 morbidity and mortality.

Purpose of the Study:

• To propose a theory identifying Type II Alveolar Epithelial Cells (AEC II) as the primary target of SARS-CoV-2.
• To elucidate the role of AEC II dysfunction in the pathogenesis of COVID-19-induced ARDS.
• To suggest potential therapeutic avenues targeting AEC II and associated molecular pathways.

Main Methods:

• This study is theoretical, proposing a specific cellular target and pathogenic mechanism.
• It involves reviewing existing literature on SARS-CoV-2 infection, lung pathology, and immune responses.
• The proposed mechanism involves a cycle of alveolar damage, inflammation, and immune cell activation.

Main Results:

• The theory posits that SARS-CoV-2 primarily infects and damages Type II Alveolar Epithelial Cells (AEC II).
• Alveolar damage initiates a pro-inflammatory cycle involving M1 macrophage polarization, cytokine release, and NF-κB pathway activation.
• This cellular and molecular cascade is proposed as the direct cause of COVID-19's clinical manifestations and ARDS.

Conclusions:

• Type II Alveolar Epithelial Cells are proposed as the key cellular targets for SARS-CoV-2.
• The dysfunction of AEC II drives the inflammatory cycle leading to ARDS in COVID-19 patients.
• Targeting AEC II and their pathogenic molecular drivers may offer effective therapeutic strategies.